Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc Administration

Lung cancer metastases to bone produce a primarily mixed osteolytic/osteoblastic lesion. The purpose of this study was to determine if blockade of both pathways would inhibit the formation these lesions in bone. Inhibition of the osteoblastic lesion with noggin and the osteolytic lesion with RANK:Fc was a successful treatment strategy to inhibit progression of mixed lung cancer lesions in bone.

[1]  E. Schwarz,et al.  Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. , 2006, Bone.

[2]  P. Robbins,et al.  Influence of BMPs on the Formation of Osteoblastic Lesions in Metastatic Prostate Cancer , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  J. Chirgwin,et al.  Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. , 2005, Cancer research.

[4]  E. Schwarz,et al.  The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone , 2005, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[5]  E. Langenfeld,et al.  Expression of bone morphogenetic proteins in human lung carcinomas. , 2005, The Annals of thoracic surgery.

[6]  D. Cameron,et al.  Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration , 2005, British Journal of Cancer.

[7]  R. Vessella,et al.  Osteoprotegerin in prostate cancer bone metastasis. , 2005, Cancer research.

[8]  A. Angelucci,et al.  Evaluation of metastatic potential in prostate carcinoma: an in vivo model. , 2004, International journal of oncology.

[9]  M. Padrines,et al.  RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. , 2004, Biochimica et biophysica acta.

[10]  D. Tripathy,et al.  Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Y. Yuasa,et al.  BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. , 2004, Biochemical and biophysical research communications.

[12]  E. Langenfeld,et al.  Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. , 2004, Molecular cancer research : MCR.

[13]  R. Taichman,et al.  Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein , 2004, Cancer Research.

[14]  W. Dougall,et al.  Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. , 2003, Cancer research.

[15]  R. Vessella,et al.  Characterization of C4–2 Prostate Cancer Bone Metastases and Their Response to Castration , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  R. O’Keefe,et al.  Molecular mechanisms of bone metastasis and therapeutic implications. , 2003, Clinical orthopaedics and related research.

[17]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. , 2003, Journal of the National Cancer Institute.

[18]  S. Calvano,et al.  The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. , 2003, Carcinogenesis.

[19]  E. Schwarz,et al.  ALK2 Functions as a BMP Type I Receptor and Induces Indian Hedgehog in Chondrocytes During Skeletal Development , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  Juan Carlos Izpisúa Belmonte,et al.  Structural Basis of BMP Signaling Inhibition by Noggin, a Novel Twelve-Membered Cystine Knot Protein , 2003, The Journal of bone and joint surgery. American volume.

[21]  J. Clement,et al.  Differential expression and regulation of bone morphogenetic protein 7 in breast cancer. , 2003, International journal of oncology.

[22]  G. Mundy,et al.  Receptor activator of NF‐κB ligand, macrophage inflammatory protein‐1α, and the proteasome , 2003 .

[23]  R. Pearse,et al.  RANK‐Fc: A therapeutic antagonist for RANK‐L in myeloma , 2003, Cancer.

[24]  K. Mohammad,et al.  Role of endothelin‐1 in osteoblastic bone metastases , 2003, Cancer.

[25]  A. Blais,et al.  Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. , 2003, Cancer research.

[26]  E. Schwarz,et al.  Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone , 2003, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[27]  E. Schwarz,et al.  Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone , 2003 .

[28]  Markus Affolter,et al.  Structural basis of BMP signalling inhibition by the cystine knot protein Noggin , 2002, Nature.

[29]  F. Saad.  Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. , 2002, Clinical prostate cancer.

[30]  R. Kitazawa,et al.  RANK ligand is a prerequisite for cancer‐associated osteolytic lesions , 2002, The Journal of pathology.

[31]  Jing Wu,et al.  Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. , 2002, Cancer research.

[32]  Johnny Huard,et al.  Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. , 2002, The Journal of clinical investigation.

[33]  K. Trieb,et al.  The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. , 2002, Journal of clinical pathology.

[34]  A. Boskey,et al.  In Vivo RANK Signaling Blockade Using the Receptor Activator of NF‐κB:Fc Effectively Prevents and Ameliorates Wear Debris‐Induced Osteolysis via Osteoclast Depletion Without Inhibiting Osteogenesis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  J. Yee,et al.  Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  K. Sugimachi,et al.  Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. , 2001, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[37]  S. F. Arnold,et al.  Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: importance of BMP2. , 1999, Cytokine.

[38]  T. Christmas,et al.  Correlation of the osteoblastic phenotype with prostate‐specific antigen expression in metastatic prostate cancer: implications for paracrine growth , 1999, The Journal of pathology.

[39]  K. Yamato,et al.  Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. , 1999, Biochemical and biophysical research communications.

[40]  H. Friess,et al.  Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. , 1999, Gastroenterology.

[41]  J. Nelson,et al.  New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. , 1999, Urology.

[42]  J. Schmitt,et al.  Bone morphogenetic proteins: An update on basic biology and clinical relevance , 1999, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[43]  Teruhiko Yoshida,et al.  Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. , 1997, Cancer research.

[44]  D. Goltzman.  Mechanisms of the development of osteoblastic metastases , 1997, Cancer.

[45]  G. Roodman,et al.  Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. , 1997, Cancer research.

[46]  Li Zhu,et al.  The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. , 2005, Anticancer research.

[47]  K. Kelly,et al.  Mechanisms of cancer metastasis to the bone , 2005, Cell Research.

[48]  Jian Zhang,et al.  Opg, RANKl, and RANK in cancer metastasis: expression and regulation. , 2004, Cancer treatment and research.

[49]  J. Huard,et al.  Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model. , 2004, The Journal of bone and joint surgery. American volume.

[50]  P. Rodrigues,et al.  Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients , 2004, Prostate Cancer and Prostatic Diseases.

[51]  増田 広.  Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer , 2004 .

[52]  J. Keenan,et al.  Patient demographics as a predictor of the ten-year survival rate in primary total knee replacement. , 2003, The Journal of bone and joint surgery. British volume.

[53]  G. Mundy,et al.  Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. , 2003, Cancer.

[54]  YQ Lin.  THE EFFECT OF CYCLOOXYGENASE-2 ( COX-2 ) INHIBITION ON HUMAN PROSTATE CANCER INDUCED OSTEOBLASTIC AND OSTEOLYTIC LESIONS IN BONE , 2003 .

[55]  P. Picci,et al.  Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. , 2002, International journal of oncology.

[56]  L. Deftos,et al.  Splenic, thymic, bony and lymph node metastases from orthotopic human lung carcinomas in immunocompromised mice. , 2000, Anticancer Research.